Acquisitive CRO BioClinica bought a firm that specializes in handling the financial side of clinical trials, picking up technology that automates how sponsors and contractors pay for studies.
Spotlight On... inVentiv opens new Phase I clinic; Pfizer taps Adaptive for immunotherapy R&D; and much more...
Risk-sharing researcher Evotec said it's advancing an early-stage Alzheimer's disease project alongside partner Johnson & Johnson, working to find new approaches to treating the neurodegenerative disorder.
Luxembourg testing outfit Eurofins is deepening its work in biopharma, acquiring a specialist in drug testing headquartered in the Netherlands.
Contract drug developer AMRI bolstered its client roster with three new agreements making use of its R&D, manufacturing and marketing divisions.
Catalent Pharma Solutions is loaning out one of its drug development platforms to Roche in a heavily back-loaded deal, signing on to reap as much as $619 million.
Canada's Altasciences is rebranding its three portfolio CROs in an effort to differentiate itself on the market for early-stage clinical research.
Belgian drugmaker UCB recruited Evotec to oversee its library of chemical compounds, enlisting the German company's expertise in hopes of easing the drug discovery process.
Charles River Laboratories extended its run of acquisitions with a $585 million buyout of WIL Research, picking up a company the CRO said will expand its global footprint and bolster its manufacturing capabilities.
PPD, rumored to be up for sale, spun out its wholly owned biotech company into a stand-alone entity, a move the CRO said will maximize shareholder value.
Spotlight On... French CRO Porsolt buys a preclinical R&D firm; FDA launches new informatics platform; and much more...
QPharma, which makes its money handling launches for drugmakers, is investing in analytics, buying an unrelated company called Qforma to better target key physicians.
Paula Brown Stafford, a 30-year-veteran of Quintiles, is planning to retire from the world's largest CRO at the end of the year, wrapping up her tenure as president of clinical development.
PDI, which long made its money helping drug companies outsource sales, is shipping off its banner business and shifting its focus to diagnostics.
Private equity giant TPG invested $75 million in Precision for Medicine, a recently formed company that partners with drugmakers to help them establish the value of in-development products.
Swedish contract drugmaker Recipharm is on board to help local biotech LIDDS advance its cancer therapy, agreeing to produce the drug and taking an equity stake in its partner.
AMRI, a contract drugmaker returning to profitability after years of restructuring, bought a New Jersey testing firm for $54 million, expanding its stable of services.
The private equity owners of CRO giant PPD are looking to either sell the company or take it public, according to Reuters, moves that would follow a trend in the pharma contracting industry.